Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • Toolbox: Coding and Computation
      • Toolbox: Signatures and Cells
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Immunology Research
Cancer Immunology Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • Toolbox: Coding and Computation
      • Toolbox: Signatures and Cells
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Clinical Trials of Cancer Immunotherapies

Abstract A009: Forty-three week follow-up of a phase 1a clinical trial of a PSA, IL-2, GM-CSF containing prostate cancer therapeutic vaccine in PSA defined biochemical recurrent prostate cancer patients

Jonathan F. Head, Gregory A. Daniels, Michelle McKinney and Jessica Wang-Rodriguez
Jonathan F. Head
Oncbiomune Pharmaceuticals, Baton Rouge, LA; VA San Diego Healthcare System, La Jolla, CA; Veterans Medical Research Foundation, La Jolla, CA.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gregory A. Daniels
Oncbiomune Pharmaceuticals, Baton Rouge, LA; VA San Diego Healthcare System, La Jolla, CA; Veterans Medical Research Foundation, La Jolla, CA.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michelle McKinney
Oncbiomune Pharmaceuticals, Baton Rouge, LA; VA San Diego Healthcare System, La Jolla, CA; Veterans Medical Research Foundation, La Jolla, CA.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jessica Wang-Rodriguez
Oncbiomune Pharmaceuticals, Baton Rouge, LA; VA San Diego Healthcare System, La Jolla, CA; Veterans Medical Research Foundation, La Jolla, CA.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/2326-6074.CRICIMTEATIAACR18-A009 Published February 2019
  • Article
  • Info & Metrics
Loading

Online Impact

Statistics from Altmetric.com

ARTICLE USAGE

ARTICLE USAGE: February 2019 to March 2021

AbstractFull-text HTMLPDF
Total42600

Cited By

Article Information

Volume 7, Issue 2 Supplement, pp. A009

DOI 
https://doi.org/10.1158/2326-6074.CRICIMTEATIAACR18-A009

Published By 
American Association for Cancer Research
Print ISSN 
2326-6066
Online ISSN 
2326-6074

Copyright & Usage 
©2019 American Association for Cancer Research.

Author Information

  1. Jonathan F. Head,
  2. Gregory A. Daniels,
  3. Michelle McKinney, and
  4. Jessica Wang-Rodriguez
  1. Oncbiomune Pharmaceuticals, Baton Rouge, LA; VA San Diego Healthcare System, La Jolla, CA; Veterans Medical Research Foundation, La Jolla, CA.
Previous
Back to top
Cancer Immunology Research: 7 (2 Supplement)
February 2019
Volume 7, Issue 2 Supplement
  • Table of Contents

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Immunology Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract A009: Forty-three week follow-up of a phase 1a clinical trial of a PSA, IL-2, GM-CSF containing prostate cancer therapeutic vaccine in PSA defined biochemical recurrent prostate cancer patients
(Your Name) has forwarded a page to you from Cancer Immunology Research
(Your Name) thought you would be interested in this article in Cancer Immunology Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Abstract A009: Forty-three week follow-up of a phase 1a clinical trial of a PSA, IL-2, GM-CSF containing prostate cancer therapeutic vaccine in PSA defined biochemical recurrent prostate cancer patients
Jonathan F. Head, Gregory A. Daniels, Michelle McKinney and Jessica Wang-Rodriguez
Cancer Immunol Res February 1 2019 (7) (2 Supplement) A009; DOI: 10.1158/2326-6074.CRICIMTEATIAACR18-A009

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract A009: Forty-three week follow-up of a phase 1a clinical trial of a PSA, IL-2, GM-CSF containing prostate cancer therapeutic vaccine in PSA defined biochemical recurrent prostate cancer patients
Jonathan F. Head, Gregory A. Daniels, Michelle McKinney and Jessica Wang-Rodriguez
Cancer Immunol Res February 1 2019 (7) (2 Supplement) A009; DOI: 10.1158/2326-6074.CRICIMTEATIAACR18-A009
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Clinical Trials of Cancer Immunotherapies

  • Abstract A007: Comparison of pretreatment conditioning on efficacy in two cohorts of a pilot study of genetically engineered NY-ESO-1c259T-cells in patients with synovial sarcoma
  • Abstract A010: Personalized neoantigen-targeting vaccines for high-risk melanoma generate epitope spreading
  • Abstract A006: Phase 1 study to evaluate the safety and tolerability of MEDI4736 (durvalumab, durva) + tremelimumab (treme) in patients with advanced solid tumors
Show more Clinical Trials of Cancer Immunotherapies

Clinical Trials of Cancer Immunotherapies: Poster Presentations - Proffered Abstracts

  • Abstract A007: Comparison of pretreatment conditioning on efficacy in two cohorts of a pilot study of genetically engineered NY-ESO-1c259T-cells in patients with synovial sarcoma
  • Abstract A010: Personalized neoantigen-targeting vaccines for high-risk melanoma generate epitope spreading
  • Abstract A006: Phase 1 study to evaluate the safety and tolerability of MEDI4736 (durvalumab, durva) + tremelimumab (treme) in patients with advanced solid tumors
Show more Clinical Trials of Cancer Immunotherapies: Poster Presentations - Proffered Abstracts
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Cancer Immunology Essentials

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Immunology Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Immunology Research
eISSN: 2326-6074
ISSN: 2326-6066

Advertisement